...IMHO "someone is going to partner with this baby" is a given and again likely before CE and to support internal trials for FDA approval. A J&J would be foolish to not lock up this technology before an FDA approval and limit their risk by partnering by proving capital up front for trials then milestone payments with option at a given point in time.
To believe that big pharma would not start to make its move after positive peer reviews of just ended test and at this stage is like concluding that big pharma only waits for phase I I I before they move in on a drug prospect...it patently false,mother move in all the time and pay up rather then having to really pay up AFTER FDA approval.
I think you are spot on! As the validation process continues partnership increases. I believe buyout chances decrease. I believe Norchi is seeing too much long term opportunity to entertain a buyout anytime soon. To your point don't think most appreciate the magnitude of where this stock is headed.
News 
Market Data 
Discover 
AI
